Tomas Olsson

Active 1984–2026

313
Papers
42,121
Citations
119
h-index
290
i10-index

Citations

Citations per year for Tomas Olsson1973: 1 citations1976: 1 citations1978: 1 citations1985: 1 citations1986: 1 citations1987: 3 citations1988: 2 citations1989: 6 citations1990: 14 citations1991: 43 citations1992: 58 citations1993: 45 citations1994: 26 citations1995: 72 citations1996: 55 citations1997: 76 citations1998: 118 citations1999: 127 citations2000: 109 citations2001: 113 citations2002: 113 citations2003: 95 citations2004: 132 citations2005: 166 citations2006: 180 citations2007: 133 citations2008: 174 citations2009: 188 citations2010: 210 citations2011: 208 citations2012: 238 citations2013: 278 citations2014: 315 citations2015: 397 citations2016: 365 citations2017: 398 citations2018: 467 citations2019: 1,448 citations2020: 1,595 citations2021: 1,611 citations2022: 1,425 citations2023: 1,055 citations2024: 1,581 citations2025: 797 citations2026: 50 citations1974–1975: no citations, so these years are not shown1977: no citations, so this year is not shown1979–1984: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,901 citing papers, 20.8% of this breakdownUnited Kingdom: 1,511 citing papers, 8% of this breakdownGermany: 1,493 citing papers, 7.9% of this breakdownSweden: 1,121 citing papers, 6% of this breakdownItaly: 1,045 citing papers, 5.6% of this breakdownChina: 950 citing papers, 5.1% of this breakdownCanada: 769 citing papers, 4.1% of this breakdownFrance: 695 citing papers, 3.7% of this breakdownSwitzerland: 621 citing papers, 3.3% of this breakdownNetherlands: 618 citing papers, 3.3% of this breakdownSpain: 601 citing papers, 3.2% of this breakdownAustralia: 537 citing papers, 2.9% of this breakdown
0%20.8%Other 26.1%

Fields

  • Medicine60.8%
  • Biochemistry, Genetics and Molecular Biology14.2%
  • Neuroscience10.3%
  • Immunology and Microbiology10.2%
  • Engineering1.3%
  • Computer Science0.9%
  • Other2.3%

Topics

  • Multiple Sclerosis Research Studies11.5%
  • Neuroinflammation and Neurodegeneration Mechanisms4.2%
  • Peripheral Neuropathies and Disorders3.7%
  • T-cell and B-cell Immunology3.1%
  • Alzheimer's disease research and treatments2.7%
  • Immunotherapy and Immune Responses2.3%
  • Other72.5%

Coauthors

All papers

Open in search
  1. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis

    Authors: , , - Nature Reviews Neurology 2016 cited by 1,174

  2. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael Jonsson, Ludwig Kappos, Mohsen Khademi, Michael Khalil, Jens Kühle, Mikael Landén, Ville Leinonen, Giancarlo Logroscino, Ching‐Hua Lu, Jan Lycke, Nadia Magdalinou, Andrea Malaspina, Niklas Mattsson, Lieke Meeter, Sanjay R. Mehta, Signe Modvig, Tomas Olsson, Ross W. Paterson, Josué Pérez‐Santiago, Fredrik Piehl, Yolande A.L. Pijnenburg, Okko T. Pyykkö, Óskar Ragnarsson, Julio C. Rojas, Jeppe Romme Christensen, Linda Sandberg, Carole Scherling, Jonathan M. Schott, Finn Sellebjerg, Isabella Laura Simone, Tobias Skillbäck, Morten Stilund, Peter Sundström, Anders Svenningsson, Rosanna Tortelli, Carla Tortorella, Alessandro Trentini, Maria Troiano, Martin R. Turner, John C. van Swieten, Mattias Vågberg, Marcel M. Verbeek, Luisa María Villar, Pieter Jelle Visser, Anders Wallin, Andreas Weiss, Carsten Wikkelsø, Edward J. Wild - JAMA Neurology 2019 cited by 760

  3. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Neurology 2021 cited by 312

  4. Locus for severity implicates CNS resilience in progression of multiple sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gıancarlo Comı, Chris Cotsapas, Bruce Cree, Sandra D’Alfonso, Efthimios Dardiotis, Philip L. De Jager, Silvia Delgado, Bénédicte Dubois, Sinah Engel, Federica Esposito, Marzena J. Fabis‐Pedrini, Massimo Filippi, Kathryn C. Fitzgerald, Christiane Gasperi, Lissette Gomez, Refujia Gomez, Georgios M. Hadjigeorgiou, Jörg Hamann, Friederike Held, Roland G. Henry, Jan Hillert, Jesse Huang, Inge Huitinga, Talat Islam, Noriko Isobe, Maja Jagodic, Allan G. Kermode, Michael Khalil, Trevor J. Kilpatrick, Ioanna Konidari, Karim L. Kreft, Jeannette Lechner‐Scott, Maurizio Leone, Felix Luessi, Sunny Malhotra, Ali Manouchehrinia, Clara P. Manrique, Filippo Martinelli Boneschi, Andrea C. Martinez, Viviana Martínez-Maldonado, Elisabetta Mascia, Luanne M. Metz, Luciana Midaglia, Xavier Montalbán, Jorge R. Oksenberg, Tomas Olsson, Annette Oturai, Kimmo Pääkkönen, Grant P. Parnell, Nikolaos A. Patsopoulos, Margaret A. Pericak‐Vance, Fredrik Piehl, Justin P. Rubio, Adam Santaniello, Silvia Santoro, Catherine Schaefer, Finn Sellebjerg, Hengameh Shams, Klementy Shchetynsky, Cláudia Silva, Vasileios Siokas, Helle Bach Søndergaard, Melissa Sorosina, Bruce Taylor, Marijne Vandebergh, Elena S. Vasileiou, Domizia Vecchio, Margarete M. Voortman, Howard L. Weiner, Dennis Wever and 21 more - Nature 2023 cited by 227

  5. Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Cell 2018 cited by 523

  6. Confounding effect of blood volume and body mass index on blood neurofilament light chain levels

    Authors: , , , , , , - Annals of Clinical and Translational Neurology 2020 cited by 247

  7. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Multiple Sclerosis Journal 2018 cited by 705

  8. Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis

    Authors: , , , , , , , , , , , , , , - Science Advances 2023 cited by 131

  9. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Barnaby Fiddes, Stephen Sawcer, Anu Kemppinen, Maria Ban, Amie Baker, Robert Andrews, Chris Cotsapas, Hannah Blackburn, Cristin McCabe, Chris Cotsapas, David A. Hafler, Chris Cotsapas, Carl A. Anderson, Jeffrey C. Barrett, Sarah Hunt, Sarah Edkins, Panos Deloukas, Tejas Shah, Hannah Blackburn, Cordelia Langford, Robert Andrews, David J. Booth, Steve Vucic, Graeme J. Stewart, Leentje Cosemans, An Goris, Bénédicte Dubois, Annette Oturai, Per Soelberg Sørensen, Helle Bach Søndergaard, Finn Sellebjerg, Janna Saarela, Virpi Leppä, Isabelle Cournu‐Rebeix, Bertrand Fontaine, Vincent Damotte, Angela Jochim, Juliane Winkelmann, Muni Hoshi, Achim Berthele, Thomas Korn, Rebecca Selter, Viola Biberacher, Volker Siffrin, Verena Grummel, Helena Kronsbein, Dorothea Buck, Laura Bergamaschi, Lucia Corrado, Filippo Martinelli-Boneschi, Claes Martin, Volker Siffrin, Frauke Zipp, Felix Luessi, Giuseppe Liberatore, Christiane Graetz, Eva Zindler, Mariaemma Rodegher, Lucia Corrado, Sandra D’Alfonso, Elisabeth G Celius, Inger-Lise Mero, Lucia Corrado, Sandra D’Alfonso, Jan Hillert, Tomas Olsson, Melissa Sorosina, Paola Brambilla, Giuseppe Liberatore, Magdalena Lindén and 93 more - Nature Genetics 2013 cited by 1,442

  10. Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2019 cited by 238

  11. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

    Authors: , , , , , , , , , , , , , , , - JAMA Neurology 2019 cited by 509

  12. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

    Authors: , , , , , , , , , , , - Neurology 2017 cited by 428

  13. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Olof Strandberg, Pia C. Sundgren, Freddy Ståhlberg, Olof Lindberg, Eric Westman, Lars‐Olof Wahlund, Per Wollmer, Ruben Smith, Tomas Olsson, Michael D. Weiner, Paul Aisen, Michael Weiner, Paul Aisen, Ronald Petersen, Clifford R. Jack, William Jagust, J.Q. Trojanowki, Arthur W. Toga, Laurel Beckett, Robert C. Green, Anthony Gamst, Andrew J. Saykin, John C. Morris, William Z. Potter, Robert C. Green, Tom Montine, Ronald Petersen, Paul Aisen, Anthony Gamst, Ronald G. Thomas, Michael Donohue, Sarah Walter, Clifford R. Jack, Anders M. Dale, Matt A. Bernstein, Joel P. Felmlee, Nick C. Fox, Paul M. Thompson, Norbert Schuff, Gene E. Alexander, Charles DeCarli, William Jagust, Dan Bandy, Robert A. Koeppe, Norm Foster, Eric M. Reiman, Kewei Chen, Chet Mathis, John C. Morris, Nigel J. Cairns, Lisa Taylor‐Reinwald, J.Q. Trojanowki, Les Shaw, Virginia M.‐Y. Lee, Magdalena Korecka, Arthur W. Toga, Karen Crawford, Scott Neu, Laurel Beckett, Danielle Harvey, Anthony Gamst, John Kornak, Andrew J. Saykin, Tatiana Foroud, Steven G. Potkin, Li Shen, Zaven Kachaturian, Richard Frank, Peter J. Snyder, Susan Molchan and 162 more - Neurology 2015 cited by 387

  14. γ-secretase directly sheds the survival receptor BCMA from plasma cells

    Authors: , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2015 cited by 364

  15. Environmental and genetic risk factors for MS: an integrated review

    Authors: , , , , , , - Annals of Clinical and Translational Neurology 2019 cited by 340

  16. Cellular architecture of evolving neuroinflammatory lesions and multiple sclerosis pathology

    Authors: , , , , , , , , , , , , , - Cell 2024 cited by 115

  17. Class II HLA interactions modulate genetic risk for multiple sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sergio E. Baranzini, Jorge R. Oksenberg, Pierre‐Antoine Gourraud, Thomas M. C. Binder, David R. Booth, Graeme J. Stewart, Calliope A Dendrou, Dorothea Buck, An Goris, Elisabeth Gulowsen Celius, Hanne F. Harbo, David A. Hafler, Frauke Zipp, Chris Cotsapas, Sandra D’Alfonso, Tomas Olsson, Calliope A. Dendrou, Bénédicte Dubois, An Goris, Bertrand Fontaine, Christina M. Lill, Christiane Graetz, Frauke Zipp, Jonathan L Haines, Adrian J Ivinson - Nature Genetics 2015 cited by 419

  18. β-amyloid Peptides and Amyloid Plaques in Alzheimer's Disease

    Authors: , , - Neurotherapeutics 2014 cited by 320

  19. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management

    Authors: , , , , , , , - EBioMedicine 2024 cited by 167

  20. Inflammation-related plasma and CSF biomarkers for multiple sclerosis

    Authors: , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2020 cited by 197

  21. Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis

    Authors: , , , , , , , , , , , , , , - Nature Communications 2023 cited by 94

  22. Lifestyle and Environmental Factors in Multiple Sclerosis

    Authors: , - Cold Spring Harbor Perspectives in Medicine 2018 cited by 225

  23. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

    Authors: , , , , , , , , , , - New England Journal of Medicine 2011 cited by 976

  24. Microglial autophagy–associated phagocytosis is essential for recovery from neuroinflammation

    Authors: , , , , , , , , , , , , , - Science Immunology 2020 cited by 148